Movement Alert｜PHARMARON Falls 4.61% in Regular Trading, CXO Sector Pullback Weighs on Shares

Market Focus11-06

On November 6, PHARMARON fell 4.61% in regular trading, trading at HK$29.34, with turnover of HK$67.91 million.

The latest market information points to a broader pullback across the CXO and life sciences tools space as the main driver of the move. In the same sector, WUXI BIO fell 2.67%, GENSCRIPT B-1K fell 10.1%, WUXI APPTEC fell 2.35%, INSILICO fell 6.25%, and WUXI XDC fell 2.42%, indicating sector-wide weakness rather than an isolated company-specific shock.

Earlier disclosures had shown PHARMARON delivered revenue of RMB12.003 billion in the first three quarters, up 19.01% year over year, and net profit attributable to shareholders of RMB1.247 billion, up 9.31%. Recent filings on controlling shareholder pledge extension also stated no impact on control and no forced liquidation risk, suggesting the current fall is more closely aligned with the latest sector retracement.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment